| Mark Taylor Jones, MD | |
|
2525 Desales Avenue, Chattanooga, TN 37404 | |
| (423) 495-7404 | |
| (423) 495-2625 |
| Full Name | Mark Taylor Jones |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 10 Years |
| Location | 2525 Desales Avenue, Chattanooga, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609294164 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 55788 (Tennessee) | Secondary |
| 207R00000X | Internal Medicine | 55788 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Adoration Home Health And Hospice Care East Tn | Cleveland, TN | Home health agency |
| Erlanger Medical Center | Chattanooga, TN | Hospital |
| Memorial Healthcare System, Inc | Chattanooga, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Erlanger Health | 1153780226 | 352 |
News Archive
A new study led by the Universities of Sheffield and Oxford with support from the UK Coronavirus Immunology Consortium (UK-CIC) has found that 99 per cent of people generate a robust immune response against Covid-19 after just one dose of the Pfizer vaccine.
Nanotechnology is advancing tools likened to Star Trek's "tricorder" that perform on-the-spot chemical analysis for a range of applications including medical testing, explosives detection and food safety.
Researchers at The University of Texas MD Anderson Cancer Center have identified eight highly specific physical and cognitive signs associated with imminent death in cancer patients. The findings, published in the journal Cancer, could offer clinicians the ability to better communicate with patients and families.
A new blood test provides a fast and accurate tool to diagnose tuberculosis in children, a new proof-of-concept study shows. The newly developed test (TAM-TB assay) is the first reliable immunodiagnostic assay to detect active tuberculosis in children.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that two oral presentations and two abstracts were delivered at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida. The presentations and abstracts highlighted clinical and preclinical progress with GlycoMimetics's lead compound GMI-1070, now in Phase 2 clinical trials in sickle cell crisis.
› Verified 7 days ago
| Entity Name | Memorial Health Partners Foundation, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922053545 PECOS PAC ID: 8022919570 Enrollment ID: O20040116000823 |
News Archive
A new study led by the Universities of Sheffield and Oxford with support from the UK Coronavirus Immunology Consortium (UK-CIC) has found that 99 per cent of people generate a robust immune response against Covid-19 after just one dose of the Pfizer vaccine.
Nanotechnology is advancing tools likened to Star Trek's "tricorder" that perform on-the-spot chemical analysis for a range of applications including medical testing, explosives detection and food safety.
Researchers at The University of Texas MD Anderson Cancer Center have identified eight highly specific physical and cognitive signs associated with imminent death in cancer patients. The findings, published in the journal Cancer, could offer clinicians the ability to better communicate with patients and families.
A new blood test provides a fast and accurate tool to diagnose tuberculosis in children, a new proof-of-concept study shows. The newly developed test (TAM-TB assay) is the first reliable immunodiagnostic assay to detect active tuberculosis in children.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that two oral presentations and two abstracts were delivered at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida. The presentations and abstracts highlighted clinical and preclinical progress with GlycoMimetics's lead compound GMI-1070, now in Phase 2 clinical trials in sickle cell crisis.
› Verified 7 days ago
| Entity Name | Chattanooga Hamilton County Hospital Authority |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154751931 PECOS PAC ID: 0547179731 Enrollment ID: O20040302001086 |
News Archive
A new study led by the Universities of Sheffield and Oxford with support from the UK Coronavirus Immunology Consortium (UK-CIC) has found that 99 per cent of people generate a robust immune response against Covid-19 after just one dose of the Pfizer vaccine.
Nanotechnology is advancing tools likened to Star Trek's "tricorder" that perform on-the-spot chemical analysis for a range of applications including medical testing, explosives detection and food safety.
Researchers at The University of Texas MD Anderson Cancer Center have identified eight highly specific physical and cognitive signs associated with imminent death in cancer patients. The findings, published in the journal Cancer, could offer clinicians the ability to better communicate with patients and families.
A new blood test provides a fast and accurate tool to diagnose tuberculosis in children, a new proof-of-concept study shows. The newly developed test (TAM-TB assay) is the first reliable immunodiagnostic assay to detect active tuberculosis in children.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that two oral presentations and two abstracts were delivered at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida. The presentations and abstracts highlighted clinical and preclinical progress with GlycoMimetics's lead compound GMI-1070, now in Phase 2 clinical trials in sickle cell crisis.
› Verified 7 days ago
| Entity Name | Erlanger Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477256303 PECOS PAC ID: 1153780226 Enrollment ID: O20230707000849 |
News Archive
A new study led by the Universities of Sheffield and Oxford with support from the UK Coronavirus Immunology Consortium (UK-CIC) has found that 99 per cent of people generate a robust immune response against Covid-19 after just one dose of the Pfizer vaccine.
Nanotechnology is advancing tools likened to Star Trek's "tricorder" that perform on-the-spot chemical analysis for a range of applications including medical testing, explosives detection and food safety.
Researchers at The University of Texas MD Anderson Cancer Center have identified eight highly specific physical and cognitive signs associated with imminent death in cancer patients. The findings, published in the journal Cancer, could offer clinicians the ability to better communicate with patients and families.
A new blood test provides a fast and accurate tool to diagnose tuberculosis in children, a new proof-of-concept study shows. The newly developed test (TAM-TB assay) is the first reliable immunodiagnostic assay to detect active tuberculosis in children.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that two oral presentations and two abstracts were delivered at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida. The presentations and abstracts highlighted clinical and preclinical progress with GlycoMimetics's lead compound GMI-1070, now in Phase 2 clinical trials in sickle cell crisis.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark Taylor Jones, MD 1949 Gunbarrel Road, Suite 230, Chattanooga, TN 37415 Ph: (423) 495-4349 | Mark Taylor Jones, MD 2525 Desales Avenue, Chattanooga, TN 37404 Ph: (423) 495-7404 |
News Archive
A new study led by the Universities of Sheffield and Oxford with support from the UK Coronavirus Immunology Consortium (UK-CIC) has found that 99 per cent of people generate a robust immune response against Covid-19 after just one dose of the Pfizer vaccine.
Nanotechnology is advancing tools likened to Star Trek's "tricorder" that perform on-the-spot chemical analysis for a range of applications including medical testing, explosives detection and food safety.
Researchers at The University of Texas MD Anderson Cancer Center have identified eight highly specific physical and cognitive signs associated with imminent death in cancer patients. The findings, published in the journal Cancer, could offer clinicians the ability to better communicate with patients and families.
A new blood test provides a fast and accurate tool to diagnose tuberculosis in children, a new proof-of-concept study shows. The newly developed test (TAM-TB assay) is the first reliable immunodiagnostic assay to detect active tuberculosis in children.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that two oral presentations and two abstracts were delivered at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida. The presentations and abstracts highlighted clinical and preclinical progress with GlycoMimetics's lead compound GMI-1070, now in Phase 2 clinical trials in sickle cell crisis.
› Verified 7 days ago
Dr. Pamela Rani Sud, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 725 Glenwood Drive, Suite E-500, Chattanooga, TN 37404 Phone: 423-495-2635 Fax: 423-495-2638 | |
David Shved, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 975 E 3rd St, Chattanooga, TN 37403 Phone: 423-778-5179 Fax: 423-778-2108 | |
Megan J Coylewright, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 975 E 3rd St, Chattanooga, TN 37403 Phone: 423-778-8258 | |
Dr. Charles Robert Bosshardt, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2515 Desales Ave Ste 206, Chattanooga, TN 37404 Phone: 423-698-8101 Fax: 423-698-3450 | |
Dr. Elise Helene Marshall, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 605 Glenwood Dr Ste 300, Chattanooga, TN 37404 Phone: 423-495-2690 Fax: 423-495-2698 | |
Dr. Joshua Warner Hornsby, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 979 E 3rd St Ste A-440, Chattanooga, TN 37403 Phone: 423-778-2867 Fax: 423-778-2866 | |
Dr. Donald Franklin Mackler, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 721 Glenwood Dr, Ste. W552, Chattanooga, TN 37404 Phone: 423-629-6258 Fax: 423-629-9531 |